Publications by authors named "Norikazu Tanabe"

Claim this Profile
E
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B.
Ryu Sasaki, Shigeo Shimose, Issei Saeki, Takanori Ito, Yasuto Takeuchi, Norikazu Tanabe

Liver Int· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study.
Takeshi Hatanaka, Shigeo Shimose, Takanori Ito, Joji Tani, Tetsu Tomonari, Norikazu Tanabe

Hepatol Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Sequential Immune Checkpoint Inhibitor Retreatment After Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.
Takanori Ito, Shigeo Shimose, Issei Saeki, Yasuto Takeuchi, Joji Tani, Norikazu Tanabe

J Gastroenterol Hepatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of Liquid Biopsy Using a Methylated SEPT9 Assay and Integrated Index for Detecting Hepatocellular Carcinoma.
Issei Saeki, Yutaka Suehiro, Yurika Yamauchi, Norikazu Tanabe, Toshihiko Matsumoto

Hepatol Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Caution Regarding Short-Term Increases in Ammonia Levels Following Splenic Artery Embolization.
Tsuyoshi Ishikawa, Aika Kirihara, Natsuko Nishiyama, Maho Egusa, Tsuyoshi Fujioka, Norikazu Tanabe

Hepatol Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The benefit of conversion therapy for patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab using newly established oncological resectability criteria in Japan.
Shigeo Shimose, Issei Saeki, Takanori Ito, Yasuto Takeuchi, Joji Tani, Norikazu Tanabe

Hepatol Int· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma.
Tetsu Tomonari, Shigeo Shimose, Issei Saeki, Joji Tani, Yuichi Honma, Norikazu Tanabe

Hepatol Res· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma.
Takanori Ito, Shigeo Shimose, Joji Tani, Tetsu Tomonari, Issei Saeki, Norikazu Tanabe

Hepatol Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma.
Norikazu Tanabe, Issei Saeki, Kenji Yamaoka, Tomokazu Kawaoka, Tetsu Tomonari

Anticancer Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Setting of Efficacy and Safety of 3 Years of Rifaximin Administration in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study.
Hideto Kawaratani, Tadashi Namisaki, Yasuteru Kondo, Ryoji Tatsumi, Naoto Kawabe, Norikazu Tanabe

J Clin Med· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination Assay of Methylated with Tumor Markers Shows High Sensitivity for Detection of Early-Stage Hepatocellular Carcinoma.
Yuki Kunimune, Yutaka Suehiro, Issei Saeki, Yurika Yamauchi, Norikazu Tanabe

Liver Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Varying Impact of Lenvatinib or Sorafenib Therapy on Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma.
Yurika Yamauchi, Issei Saeki, Koichi Fujisawa, Maho Egusa, Natsuko Nishiyama, Norikazu Tanabe

Oncology· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.
Issei Saeki, Shigeo Shimose, Tetsu Tomonari, Takanori Ito, Joji Tani, Norikazu Tanabe

PLoS One· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice.
Shigeo Shimose, Issei Saeki, Tetsu Tomonari, Takanori Ito, Joji Tani, Norikazu Tanabe

Oncol Lett· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma.
Issei Saeki, Yutaka Suehiro, Yurika Yamauchi, Tomomi Hoshida, Norikazu Tanabe

Hepatol Int· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double cancer of primary hepatic angiosarcoma and hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
Yurika Yamauchi, Issei Saeki, Takahiro Yamasaki, Maho Egusa, Natsuko Nishiyama, Norikazu Tanabe

Hepatol Res· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma.
Norikazu Tanabe, Issei Saeki, Yuki Aibe, Takashi Matsuda, Tadasuke Hanazono

Cancers (Basel)· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A combination of liver stiffness and international normalized ratio is an ideal prognostic predictor of portosystemic shunt occlusion in patients with portal hypertension.
Tsuyoshi Ishikawa, Maho Egusa, Tsuyoshi Fujioka, Natsuko Nishiyama, Daiki Kawamoto, Norikazu Tanabe

J Gastroenterol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Efficacy and Safety of Rifaximin in Japanese Patients with Hepatic Encephalopathy: A Multicenter Retrospective Study.
Hideto Kawaratani, Yasuteru Kondo, Ryoji Tatsumi, Naoto Kawabe, Norikazu Tanabe

J Clin Med· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Albumin-bilirubin score as a useful predictor of energy malnutrition in patients with hepatocellular carcinoma.
Yurika Kotoh, Issei Saeki, Takahiro Yamasaki, Ryo Sasaki, Norikazu Tanabe

Clin Nutr· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model.
Norikazu Tanabe, Taro Takami, Koichi Fujisawa, Toshihiko Matsumoto, Naoki Yamamoto

J Clin Biochem Nutr· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy.
Issei Saeki, Takahiro Yamasaki, Norikazu Tanabe, Takuya Iwamoto, Toshihiko Matsumoto

PLoS One· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis